Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions
Abstract Gastrointestinal (GI) cancers are a significant global health concern with diverse etiologies and limited treatment options. Ellagic acid (EA), a natural polyphenolic compound, exhibits promising anticancer properties against various GI malignancies. In this article, we have reviewed recent...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-09-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-024-00296-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162618279395328 |
|---|---|
| author | Abhishek Chauhan Monika Yadav Ritu Chauhan Rupesh Kumar Basniwal Vinay Mohan Pathak Anuj Ranjan Raj Kishor Kapardar Rajpal Srivastav Hardeep Singh Tuli Seema Ramniwas Darin Mansor Mathkor Shafiul Haque Arif Hussain |
| author_facet | Abhishek Chauhan Monika Yadav Ritu Chauhan Rupesh Kumar Basniwal Vinay Mohan Pathak Anuj Ranjan Raj Kishor Kapardar Rajpal Srivastav Hardeep Singh Tuli Seema Ramniwas Darin Mansor Mathkor Shafiul Haque Arif Hussain |
| author_sort | Abhishek Chauhan |
| collection | DOAJ |
| description | Abstract Gastrointestinal (GI) cancers are a significant global health concern with diverse etiologies and limited treatment options. Ellagic acid (EA), a natural polyphenolic compound, exhibits promising anticancer properties against various GI malignancies. In this article, we have reviewed recent research on the anticancer potential of EA across esophageal, gastric, colorectal, pancreatic, and liver cancers. In esophageal cancer, EA inhibits the formation of O6-methylguanine (O6-meGua) adducts induced by carcinogens like N-nitrosomethylbenzylamine (NMBA), thereby suppressing tumor growth. Additionally, EA inhibits STAT3 signaling and stabilizes tumor suppressor proteins, showing potential as an anti-esophageal cancer agent. In gastric cancer, EA regulates multiple pathways involved in cell proliferation, invasion, and apoptosis, including the p53 and PI3K-Akt signaling pathways. It also demonstrates anti-inflammatory and antioxidant effects, making it a promising therapeutic candidate against gastric cancer. In colorectal cancer (CRC), EA inhibits cell proliferation, induces apoptosis, and modulates the Wnt/β-catenin and PI3K/Akt pathways, suggesting its efficacy in preventing CRC progression. Furthermore, EA has shown promise in pancreatic cancer by inhibiting nuclear factor-kappa B, inducing apoptosis, and suppressing epithelial–mesenchymal transition. In liver cancer, EA exhibits radio-sensitizing effects, inhibits inflammatory pathways, and modulates the tumor microenvironment, offering potential therapeutic benefits against hepatocellular carcinoma. Studies on EA potential in combination therapies and the development of targeted delivery systems are required for enhanced efficacy against gastrointestinal cancers. |
| format | Article |
| id | doaj-art-e4a19be511db4afdbac5acbbfc8880be |
| institution | OA Journals |
| issn | 2366-1070 2366-1089 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Oncology and Therapy |
| spelling | doaj-art-e4a19be511db4afdbac5acbbfc8880be2025-08-20T02:22:30ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892024-09-0112468569910.1007/s40487-024-00296-1Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future DirectionsAbhishek Chauhan0Monika Yadav1Ritu Chauhan2Rupesh Kumar Basniwal3Vinay Mohan Pathak4Anuj Ranjan5Raj Kishor Kapardar6Rajpal Srivastav7Hardeep Singh Tuli8Seema Ramniwas9Darin Mansor Mathkor10Shafiul Haque11Arif Hussain12Amity Institute of Environmental Toxicology Safety and Management, Amity UniversityCancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru UniversityDepartment of Biotechnology, Graphic Era Deemed to be UniversityAmity Institute of Advanced Research and Studies (M&D), Amity UniversityParwatiya Shiksha Sabha (PASS), Near Transport Nagar Develchaur KhamAcademy of Biology and Biotechnology, Southern Federal UniversityThe Energy and Resources InstituteAmity Institute of Biotechnology, Amity University Uttar PradeshDepartment of Biosciences and Technology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to be University)University Centre for Research and Development, University Institute of Pharmaceutical Sciences, Chandigarh UniversityResearch and Scientific Studies Unit, College of Nursing and Health Sciences, Jazan UniversityResearch and Scientific Studies Unit, College of Nursing and Health Sciences, Jazan UniversitySchool of Life Sciences, Manipal Academy of Higher EducationAbstract Gastrointestinal (GI) cancers are a significant global health concern with diverse etiologies and limited treatment options. Ellagic acid (EA), a natural polyphenolic compound, exhibits promising anticancer properties against various GI malignancies. In this article, we have reviewed recent research on the anticancer potential of EA across esophageal, gastric, colorectal, pancreatic, and liver cancers. In esophageal cancer, EA inhibits the formation of O6-methylguanine (O6-meGua) adducts induced by carcinogens like N-nitrosomethylbenzylamine (NMBA), thereby suppressing tumor growth. Additionally, EA inhibits STAT3 signaling and stabilizes tumor suppressor proteins, showing potential as an anti-esophageal cancer agent. In gastric cancer, EA regulates multiple pathways involved in cell proliferation, invasion, and apoptosis, including the p53 and PI3K-Akt signaling pathways. It also demonstrates anti-inflammatory and antioxidant effects, making it a promising therapeutic candidate against gastric cancer. In colorectal cancer (CRC), EA inhibits cell proliferation, induces apoptosis, and modulates the Wnt/β-catenin and PI3K/Akt pathways, suggesting its efficacy in preventing CRC progression. Furthermore, EA has shown promise in pancreatic cancer by inhibiting nuclear factor-kappa B, inducing apoptosis, and suppressing epithelial–mesenchymal transition. In liver cancer, EA exhibits radio-sensitizing effects, inhibits inflammatory pathways, and modulates the tumor microenvironment, offering potential therapeutic benefits against hepatocellular carcinoma. Studies on EA potential in combination therapies and the development of targeted delivery systems are required for enhanced efficacy against gastrointestinal cancers.https://doi.org/10.1007/s40487-024-00296-1Ellagic acidGastrointestinal malignanciesGastroprotectiveChemopreventiveTherapeutic resistance |
| spellingShingle | Abhishek Chauhan Monika Yadav Ritu Chauhan Rupesh Kumar Basniwal Vinay Mohan Pathak Anuj Ranjan Raj Kishor Kapardar Rajpal Srivastav Hardeep Singh Tuli Seema Ramniwas Darin Mansor Mathkor Shafiul Haque Arif Hussain Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions Oncology and Therapy Ellagic acid Gastrointestinal malignancies Gastroprotective Chemopreventive Therapeutic resistance |
| title | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| title_full | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| title_fullStr | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| title_full_unstemmed | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| title_short | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| title_sort | exploring the potential of ellagic acid in gastrointestinal cancer prevention recent advances and future directions |
| topic | Ellagic acid Gastrointestinal malignancies Gastroprotective Chemopreventive Therapeutic resistance |
| url | https://doi.org/10.1007/s40487-024-00296-1 |
| work_keys_str_mv | AT abhishekchauhan exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT monikayadav exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT rituchauhan exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT rupeshkumarbasniwal exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT vinaymohanpathak exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT anujranjan exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT rajkishorkapardar exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT rajpalsrivastav exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT hardeepsinghtuli exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT seemaramniwas exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT darinmansormathkor exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT shafiulhaque exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections AT arifhussain exploringthepotentialofellagicacidingastrointestinalcancerpreventionrecentadvancesandfuturedirections |